ArticleOncotarget2017
The tumor suppressor capability of p53 is dependent on non-muscle myosin IIA function in head and neck cancer.
Article in Oncotarget, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 32 citations in OpenAlex.
- hsa_circ_0063865 regulates cytoskeleton rearrangement and endoplasmic reticulum stress to promote esophageal tumorigenesis under co-exposure to N-nitrosamines and microcystin.Journal of translational medicine · 2026Article
- OTUD4 Inhibits Prostate Cancer by Deubiquitinating MYH9.Oncology research · 2026Article
- Article
- Article
- Non-Muscle Myosin II A: Friend or Foe in Cancer?International journal of molecular sciences · 2024Review
- Disulfidptosis, A Novel Cell Death Pathway: Molecular Landscape and Therapeutic Implications.Aging and disease · 2024Review
- Exploring the nexus between MYH9 and tumors: novel insights and new therapeutic opportunities.Frontiers in cell and developmental biology · 2024Review
- Effective-Component Compatibility of Bufei Yishen Formula III Suppresses Mitochondrial Oxidative Damage in COPD: Via Pkm2/Nrf2 Pathway.International journal of chronic obstructive pulmonary disease · 2024Article
- CircSP3 encodes SP3-461aa to promote ccRCC progression via stabilizing MYH9 and activating the PI3K-Akt signaling pathway.Journal of Cancer · 2024Article
- HER2 inhibition increases non-muscle myosin IIA to promote tumorigenesis in HER2+ breast cancers.PloS one · 2023Article
- Article
- "MYH9 mutation and squamous cell cancer of the tongue in a young adult: a novel case report".Diagnostic pathology · 2022Article
- circ-EIF6 encodes EIF6-224aa to promote TNBC progression via stabilizing MYH9 and activating the Wnt/beta-catenin pathway.Molecular therapy : the journal of the American Society of Gene Therapy · 2022Article
- MYH9 is crucial for stem cell-like properties in non-small cell lung cancer by activating mTOR signaling.Cell death discovery · 2021Article
- The mechanobiome: a goldmine for cancer therapeutics.American journal of physiology. Cell physiology · 2021Review
- MYH9 suppresses melanoma tumorigenesis, metastasis and regulates tumor microenvironment.Medical oncology (Northwood, London, England) · 2020Article
- Review
- MYH9 overexpression correlates with clinicopathological parameters and poor prognosis of epithelial ovarian cancer.Oncology letters · 2019Article
- Deciphering the Mammary Stem Cell Niche: A Role for Laminin-Binding Integrins.Stem cell reports · 2019Article
- Myosin Heavy Chain 9: Oncogene or Tumor Suppressor Gene?Medical science monitor : international medical journal of experimental and clinical research · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 1 country.
Funding
Abstract
Over 300,000 patients develop squamous cell carcinoma of the head and neck (HNSCC) worldwide with 25-30% of patients ultimately dying from their disease. Currently, molecular biomarkers are not used in HNSCC but several genes have been identified including mutant TP53 (mutp53). Our recent work has identified an approach to stratify patients with tumors harboring high or low risk TP53 mutations. Non-muscle Myosin IIA (NMIIA) was recently identified as a tumor suppressor in HNSCC. We now demonstrate that low MYH9 expression is associated with decreased survival in patients with head and neck cancer harboring low-risk mutp53 but not high-risk mutp53. Furthermore, inhibition of NMIIA leads to increased invasion in cells harboring wildtype p53 (wtp53), which was not observed in high-risk mutp53 cells. This increased invasiveness of wtp53 following NMIIA inhibition was associated with reduced p53 target gene expression and was absent in cells expressing mutp53. This reduced expression may be due, in part, to a decrease in nuclear localization of wtp53. These findings suggest that the tumor suppressor capability of wtp53 is dependent upon functional NMIIA and that the invasive phenotype of high-risk mutp53 is independent of NMIIA.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.